Program
amrubicin
Also written as “Amrubicin”, “Amrubicin Hydrochloride” and “Amrubicin (Japan only)”.
Its studies are mostly in Small Cell Lung Carcinoma · Lung Neoplasms · Breast Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bristol-Myers Squibb | 60 open or running | phase 3since Oct 18, 2007 | Apr 27, 2006 | none ahead |
| Sumitomo Pharma | 20 open or running | phase 3since Feb 1, 2006 | Feb 1, 2006 | none ahead |
| Gilead Sciences | 11 open or running | phase 3since Jan 24, 2025 | Jan 24, 2025 | Oct 2029phase 3 · NCT06801834 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 1, 2006First study: phase 3 study in Small Cell Lung CarcinomaNew to Sumitomo PharmaSumitomo Pharma · NCT00286169 · 130 enrolled · Japan
- Apr 27, 2006Bristol-Myers Squibb's first study: phase 2 study in Small Cell Lung CarcinomaNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT00319969 · 76 enrolled · United States
- Sep 9, 20062 phase 2 studiesBristol-Myers Squibb · NCT00375193, NCT00380835
- Oct 13, 2006Phase 2 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT00388960 · 99 enrolled · Belgium, Italy, Netherlands and more
- Oct 18, 2007Phase 3 study in Small Cell Lung CarcinomaBristol-Myers Squibb · NCT00547651 · 637 enrolled · United States, Australia, Austria and more
- Apr 10, 2008Phase 3 study in Lung NeoplasmsSumitomo Pharma · NCT00660504 · 300 enrolled · China
- Jun 4, 2009Phase 1 study in Advanced Solid TumorsBristol-Myers Squibb · NCT00915083 · 24 enrolled · United States
- Jan 24, 2025Gilead Sciences's first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
Ahead
- Oct 2029Primary completion: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)Gilead Sciences · NCT06801834
TargetBeta
“DNA topoisomerase II alpha inhibitor; DNA topoisomerase II alpha inhibitor”ChEMBL 37, by rule
Other programs on TOP2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Doxorubicinrule | Hoffmann-La Roche | phase 4 | 61 |
| Etoposiderule | Hoffmann-La Roche | phase 3 | 28 |
| Daunorubicinrule | kura-oncology-inc | phase 3 | 7 |
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more | 3 | Recruiting | Gilead Sciences | Oct 2029 | 695 |
| NCT00915083Advanced Solid Tumors · United States | 1 | Completed | Bristol-Myers Squibb | May 1, 2011 | 24 |
| NCT00660504Lung Neoplasms · China | 3 | Completed | Sumitomo Pharma | Feb 2012 | 300 |
| NCT00547651Small Cell Lung Carcinoma · United States, Australia, Austria and more | 3 | Completed | Bristol-Myers Squibb | May 1, 2011 | 637 |
| NCT00388960Small Cell Lung Carcinoma · Belgium, Italy, Netherlands and more | 2 | Completed | Bristol-Myers Squibb | Apr 1, 2010 | 99 |
| NCT00380835Breast Neoplasms · United States | 2 | Withdrawn | Bristol-Myers Squibb | 66 | |
| NCT00375193Small Cell Lung Carcinoma · United States, Netherlands, United Kingdom | 2 | Completed | Bristol-Myers Squibb | May 1, 2008 | 75 |
| NCT00319969Small Cell Lung Carcinoma · United States | 2 | Completed | Bristol-Myers Squibb | Jul 2008 | 76 |
| NCT00286169Small Cell Lung Carcinoma · Japan | 3 | Terminated | Sumitomo Pharma | 130 |
How it is read
Names in the registry
- “Amrubicin”, 6 entries
- “Amrubicin Hydrochloride”, 2 entries
- “Amrubicin (Japan only)”, 1 entry
Conditions, from the studies’ own filings
- Small Cell Lung Carcinoma, 6 studies
- Lung Neoplasms, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.